New agents for the treatment of renal cell carcinoma.
One-third of patients with renal cell carcinoma present with unresectable or metastatic disease. Immunotherapy, the current standard treatment, induces response in only 10-20% of patients. Chemotherapy with current agents is minimally effective. Other approaches including allogeneic stem cell transplant, vaccine and gene therapy and signal transduction inhibitors, offer promise in early Phase studies. This paper reviews the current treatment options and promising new agents in development.
Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, 22 South Greene Street, Baltimore, MD 21201, USA.
G G
GG
Tian
N A
NA
Dawson
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000628:therapy; D016207:Cytokines / Q000627:therapeutic use*; D004358:Drug Therapy; D016228:Endothelial Growth Factors / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000627:therapeutic use; D005346:Fibroblast Growth Factors / Q000627:therapeutic use; D015316:Genetic Therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000639:trends*; D006801:Humans; D007167:Immunotherapy; D016233:Immunotherapy, Active; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000628:therapy; D008222:Lymphokines / Q000627:therapeutic use; D014184:Transplantation, Homologous; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D016207:Cytokines; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D005346:Fibroblast Growth Factors; D004815:Epidermal Growth Factor